Platelet-mitochondria dual-targeted nanocarriers for enhanced empagliflozin therapy in atherosclerosis

IntroductionAtherosclerosis (AS) is a primary cause of cardiovascular disease and significantly contributes to the global disease burden. Empagliflozin (EMP), a candidate drug for AS treatment, has not been clinically approved due to challenges including poor solubility, low bioavailability, and pot...

全面介紹

書目詳細資料

發表在:	Frontiers in Bioengineering and Biotechnology
Main Authors:	Yue Tang, Yue Tian, Yi Wang, Xue Mei, Lijun Luo, Fan Zhang, XiaoJin Gao, Yihua Wang, Jun Hou, Chunyang Zhou
格式:	Article
語言:	英语
出版:	Frontiers Media S.A. 2025-09-01
主題:	atherosclerosis empagliflozin platelet membrane-cloaked nanoparticles targeted delivery mitochondria-targeted
在線閱讀:	https://www.frontiersin.org/articles/10.3389/fbioe.2025.1638034/full